Stifel Designates DexCom as Top Med-Tech Pick on Strong Growth Outlook

Investment firm Stifel has identified DexCom (NASDAQ:DXCM) as its leading investment idea in the medical technology and supplies sector, following the diabetes monitoring company's robust second-quarter 2026 performance and an upgraded full-year forecast.

Strong Quarterly Results Drive Optimism

DexCom's recent financial results surpassed analyst expectations across all key metrics, including revenue, gross margin, operating margin, and earnings per share. The company reported second-quarter revenue of $1.308 billion, a 12% year-over-year increase on an organic basis that exceeded consensus estimates. Following the strong performance, DexCom raised its 2026 guidance for both organic revenue growth and margins.

According to Stifel's analysis, which aligns with its recent survey data, DexCom appears to have achieved long-term U.S. market share gains for the first time in years. This shift in competitive dynamics is a key factor in the firm's positive assessment.

Key Growth Catalysts Identified

Stifel highlighted several pathways for DexCom's continued success, underscoring a multi-year growth trajectory. The firm pointed to several key catalysts that could drive future performance:

Ad

• Market Expansion: A significant opportunity exists in the Type 2 non-insulin treated diabetes market. This initiative remains on track for a year-end 2026 launch, with broader insurance coverage anticipated by mid-2027.
• Product Innovation: The company's 15-Day product is expected to be an early-stage driver for revenue growth, while the planned G8 product launch in 2028 and beyond provides a longer-term catalyst.
• Margin Expansion: DexCom has a multi-year roadmap for improving gross margins, with benefits expected from its U.S. 15-Day product in 2026-2027 and internationally in 2027-2028.
• International Opportunities: The company is also positioned to capitalize on additional growth in markets outside the U.S.

Analyst Upgrades and Price Target

In response to the company's performance and outlook, Stifel raised its earnings estimates for DexCom for 2026 through 2028 and set a price target of $95 per share. The positive sentiment is shared by other financial institutions.

Following the earnings report, several other analyst firms, including RBC Capital, BTIG, and Truist Securities, also raised their price targets for DexCom. This broad-based analyst support signals growing confidence in the company's strategic direction and its ability to execute on its growth initiatives.